|
Market Closed -
Nasdaq
21:00:00 06/11/2026 GMT
|
5-day change | 1st Jan Change | ||
| 547.09 USD | +0.85% |
|
+1.31% | +20.67% |
| 11-04 | Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $620 From $608 | MT |
| 11-03 | Vertex Stock May See Further Appreciation on Approval, Launch of Povetacicept, RBC Says | MT |
Company Valuation: Vertex Pharmaceuticals Incorporated
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55,834 | 74,127 | 104,849 | 103,707 | 115,026 | 137,544 | - | - |
| Change | - | 32.76% | 41.44% | -1.09% | 10.91% | 19.58% | - | - |
| Enterprise Value (EV) 1 | 48,309 | 63,349 | 93,630 | 97,591 | 108,418 | 134,785 | 131,840 | 128,217 |
| Change | - | 31.13% | 47.8% | 4.23% | 11.09% | 24.32% | -2.18% | -2.75% |
| P/E | 24.4x | 22.5x | 29.3x | -194x | 29.6x | 38.6x | 30.9x | 24.5x |
| PBR | 5.53x | 5.33x | 5.96x | 6.4x | 6.17x | 6.23x | 5.44x | 4.98x |
| PEG | - | 0.5x | 3.51x | 2x | -0x | -5.14x | 1.2x | 0.9x |
| Capitalization / Revenue | 7.37x | 8.3x | 10.6x | 9.41x | 9.58x | 10.4x | 9.4x | 8.32x |
| EV / Revenue | 6.38x | 7.09x | 9.49x | 8.86x | 9.03x | 10.2x | 9.01x | 7.76x |
| EV / EBITDA | 10.8x | 12.8x | 20.6x | 108x | 19.8x | 24x | 21.1x | 17.8x |
| EV / EBIT | 11.1x | 13.2x | 21.4x | 140x | 20.6x | 24.9x | 21.7x | 17.5x |
| EV / FCF | 20.1x | 16.1x | 28.1x | -123x | 33.9x | 18x | 22.8x | 18.1x |
| FCF Yield | 4.99% | 6.2% | 3.56% | -0.81% | 2.95% | 5.56% | 4.39% | 5.54% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 | 14.17 | 17.69 | 22.33 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 | 13,248 | 14,633 | 16,523 |
| EBITDA 1 | 4,470 | 4,941 | 4,556 | 902.8 | 5,473 | 5,620 | 6,247 | 7,198 |
| EBIT 1 | 4,344 | 4,793 | 4,375 | 695.6 | 5,263 | 5,402 | 6,068 | 7,309 |
| Net income 1 | 2,342 | 3,322 | 3,620 | -535.6 | 3,953 | 3,630 | 4,557 | 5,764 |
| Net Debt 1 | -7,525 | -10,778 | -11,218 | -6,116 | -6,608 | -2,759 | -5,704 | -9,327 |
| Reference price 2 | 219.60 | 288.78 | 406.89 | 402.70 | 453.36 | 547.09 | 547.09 | 547.09 |
| Nbr of stocks (in thousands) | 254,252 | 256,691 | 257,683 | 257,529 | 253,719 | 253,538 | - | - |
| Announcement Date | 26/01/22 | 07/02/23 | 05/02/24 | 10/02/25 | 12/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 35.5x | 10.17x | 23.98x | -.--% | 138B | |
| 39.94x | 13.51x | 30.01x | 0.5% | 1,216B | |
| 39.86x | 6.69x | 18.83x | 1.96% | 656B | |
| 37.08x | 8.43x | 17.39x | 2.4% | 509B | |
| 21.12x | 5.13x | 12.77x | 2.56% | 384B | |
| 97.32x | 5.95x | 25.36x | 2.32% | 362B | |
| 23.5x | 6.02x | 14.53x | 2.65% | 311B | |
| 24.85x | 4.96x | 13.98x | 1.76% | 293B | |
| 28.41x | 7.33x | 12.69x | 2.19% | 249B | |
| -40.11x | 7.32x | 45.99x | 1.97% | 208B | |
| Average | 30.75x | 7.55x | 21.55x | 1.83% | 432.53B | |
| Weighted average by Cap. | 35.87x | 8.62x | 22.29x | 1.67% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- VRTX Stock
- Valuation Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
